Collagen alpha-2(VI) chain (COL6A2)

Collagen alpha-2(VI) chain (COL6A2) is a vital structural component of the extracellular matrix, specifically forming the alpha-2 subunit of type VI collagen. This protein is essential for maintaining the mechanical integrity of skeletal muscle and skin by forming a microfibrillar network that bridges the basement membrane and the interstitial matrix (UniProt: P12107). Mutations in the COL6A2 gene are the primary cause of Collagen VI-related dystrophies, including the severe Ullrich congenital muscular dystrophy and the milder Bethlem myopathy (NCBI Gene: 1292). These conditions often arise from dominant-negative mutations where the mutant protein interferes with the assembly of the collagen VI heterotrimer, leading to a dysfunctional matrix and progressive muscle degeneration (PubMed: 24503413). Therapeutic development targeting COL6A2 mutant alleles focuses on precision genetic approaches, such as allele-specific siRNA or antisense oligonucleotides, designed to selectively degrade mutant mRNA while sparing the wild-type transcript (PubMed: 24503413). By reducing the expression of the toxic mutant protein, these therapies aim to allow the remaining wild-type protein to form a functional, albeit reduced, extracellular matrix, potentially halting disease progression. Additionally, CRISPR/Cas9-based gene editing is being explored to permanently disrupt the mutant allele in a patient-specific manner (PubMed: 28820136). These strategies represent a shift toward personalized medicine for rare genetic disorders where traditional protein replacement is challenging due to the complex assembly requirements of collagen VI.

Other names

Collagen type VI alpha 2Alpha-2 type VI collagenBTHLM1UCMD1PP1020

Allele-specific knockdown of mutant transcripts to prevent dominant-negative interference with collagen VI assembly